文献速递前列腺癌

靶向前列腺特异性膜抗原的放射性示踪剂显像检测根治性治疗后前列腺癌生化复发:系统综述与Meta分析

Imaging of Prostate Specific Membrane Antigen Targeted Radiotracers for the Detection of Prostate Cancer Biochemical Recurrence after Definitive Therapy: A Systematic Review and Meta-Analysis.
PubMed 文献 · J Urol · 2019-07-08

该系统综述与Meta分析纳入43项研究共5113例根治性治疗后生化复发且无已知转移的前列腺癌患者,评估前列腺特异性膜抗原靶向PET/CT的检出率。汇总检出率为70.2%(95%CI 65.0-75.4),检出率随PSA水平升高而增加,PSA<0.5、0.5-0.9、1-1.9和≥2 ng/ml时分别为44.9%、61.3%、78.2%和93.9%。作者认为该显像在低PSA水平也可能有效,但现有研究受回顾性设计、参考标准有限、发表偏倚及缺乏示踪剂间比较的限制。

要点

  • 汇总检出率为70.2%(95%CI 65.0-75.4),PSA≥2 ng/ml时达93.9%。
  • PSA<0.5 ng/ml时检出率仍为44.9%(95%CI 36.0-53.9)。
  • 研究间存在显著异质性和发表偏倚(p<0.01)。

核心结论

  • 前列腺特异性膜抗原靶向放射性示踪剂可能在低前列腺特异性抗原水平有效检测生化复发的前列腺癌。
  • 现有研究受回顾性设计、参考标准有限、发表偏倚及缺乏示踪剂间比较的限制。

研究设计与样本

  • 按照PRISMA-DTA指南,检索PubMed和EMBASE数据库2012年至2018年7月的文献。
  • 纳入根治性治疗后生化复发且无已知转移、接受PSMA PET/CT检测复发的前列腺癌患者研究。
  • 共纳入43项研究、5113例患者;15项(34.8%)为前瞻性,3项(6.9%)为多机构研究,其余为单中心。
  • 18项(41.8%)研究在根治性前列腺切除术后患者中进行,2项(4.6%)在放疗后,23项(53.5%)在根治性前列腺切除术后加放疗后。
  • 中位PSA为1.6 ng/ml(IQR 0.7-4.4),中位年龄68岁(IQR 67-70);33项(76.7%)研究评估68Ga-PSMA-11(Ga-HBED-CC)PET/CT。

主要发现

  • 整个队列的汇总检出率为70.2%(95%CI 65.0-75.4)。
  • PSA<0.5、0.5-0.9、1-1.9和≥2 ng/ml的汇总检出率分别为44.9%(95%CI 36.0-53.9)、61.3%(95%CI 52.3-70.3)、78.2%(95%CI 70.8-85.6)和93.9%(95%CI 92.0-95.8)。
  • 715例患者中684例(95.7%)参考标准确认为阳性。
  • 存在显著的研究异质性和发表偏倚(p<0.01)。

关键数值与推荐

  • 参考标准为病理结果、随访影像或挽救性治疗后PSA下降。
  • 使用QUADAS-2评估偏倚风险和适用性担忧。
  • 使用Cochrane Q和I2估计评估统计异质性。
  • 采用随机效应模型计算汇总估计值及95%CI。

局限性

  • 现有研究受回顾性设计限制。
  • 参考标准有限。
  • 存在发表偏倚(p<0.01)。
  • 缺乏示踪剂间比较。
  • 存在显著的研究异质性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Prostate specific membrane antigen targeted radiotracers are promising agents for imaging patients with prostate cancer biochemical recurrence after definitive therapy. We report the results of a systematic review and meta-analysis of the detection of biochemical recurrence after definitive therapy for prostate cancer stratified by prostate specific antigen levels and using prostate specific membrane antigen targeted radiotracers. MATERIALS AND METHODS: According to the Preferred Reporting Items for Systematic reviews and Meta-Analysis Diagnostic Test Accuracy guidelines, we searched for articles in PubMed® and EMBASE® databases in our systematic review from 2012 to July 2018. Studies evaluating men with prostate cancer biochemical recurrence after definitive therapy and without known metastatic disease who underwent prostate specific membrane antigen positron emission tomography/computerized tomography to detect recurrent disease were included in analysis. The risk of bias and applicability concerns were assessed by QUADAS-2 (Quality Assessment of Diagnostic Accuracy Studies 2). Statistical heterogeneity was assessed with the Cochrane Q and an I2 estimate. The reference standard was pathology findings, followup imaging or a prostate specific antigen decline after salvage treatment. We calculated pooled estimates and the 95% CI around the prevalence of a positive examination in the study population using a random effects model. RESULTS: A total of 5,113 patients in 43 studies were included in this systematic review. Of the studies 15 (34.8%) were prospective, 3 (6.9%) were multi-institutional and the remainder were done at a single center. A total of 18 studies (41.8%) were done in subjects after radical prostatectomy, 2 (4.6%) were in subjects after radiotherapy and 23 (53.5%) were in subjects after radical prostatectomy and radiotherapy. Median prostate specific antigen was 1.6 ng/ml (IQR 0.7-4.4) and median subject age was 68 years (IQR 67-70). Of the 43 studies 33 (76.7%) evaluated 68Ga prostate specific membrane antigen-11 (Ga-HBED-CC) positron emission tomography/computerized tomography. The pooled detection rate was 70.2% (95% CI 65.0-75.4) in the entire cohort. For prostate specific antigen less than 0.5, 0.5 to 0.9, 1 to 1.9 and 2 ng/ml or greater the pooled detection rate was 44.9% (95% CI 36.0-53.9), 61.3% (95% CI 52.3-70.3), 78.2% (95% CI 70.8-85.6) and 93.9% (95% CI 92.0-95.8), respectively. A reference standard was confirmed to be positive in 684 of the 715 patients (95.7%). There were significant study heterogeneity and publication biases (p <0.01). CONCLUSIONS: Prostate specific membrane antigen targeted radiotracers are likely effective to detect biochemically recurrent prostate cancer at low prostate specific antigen levels. However, existing studies are limited by retrospective design, limited reference standards, publication bias and a lack of interagent comparison.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Tan N, Bavadian N, Calais J, et al. Imaging of Prostate Specific Membrane Antigen Targeted Radiotracers for the Detection of Prostate Cancer Biochemical Recurrence after Definitive Therapy: A Systematic Review and Meta-Analysis. J Urol. 2019. PMID: 30829130. doi:10.1097/JU.0000000000000198

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。